Pharmaceutical compositions comprising trimegestone
AssigneeAventis Pharma S.A.
InventorsPhilippe Becourt, Robert Georges, Serge Segot Chicq
Life of this patent
Estimating the term…
Abstract
The invention concerns a pharmaceutical composition comprises trimegestone optionally associated with an oestrogen, characterized in that it comprises a buffer solution whereof the pH, when it is introduced in the composition, ranging essentially between 2 and 5.5. The invention also concerns the methods for making such a composition and the primary package containing them.
Claims19
A pharmaceutical composition in solid form for oral administration, comprising by percentage of total weight:
- 0.05% to 3% of trimegestone,
- 0.30% to 6% of estrogen,
- 0% to 2% titanium dioxide,
- 0.1% to 2% of a buffer comprising citric acid and disodium phosphate, the pH of which is essentially between 2 and 5.5,
- 0% to 4% of stearic, talc, or a combination of stearic acid and talc,
- 0% to 0.2% of a chelating agent, and
- qs diluent.
A pharmaceutical composition in solid form for oral administration, which contains a buffer having a pH essentially between 2 and 5.5 and which composition comprises by percentage of total weight:
- 0.4% of trimegestone,
- 3.2% of estradiol,
- 4% of HPMC,
- 1% of titanium dioxide,
- 0.15% of anhydrous disodium phosphate,
- 0.4% of citric acid monohydrate,
- 31% of maize starch,
- 0.6% of stearic acid,
- 1.2% of talc,
- 0.1% of EDTA and
- qs of lactose.
A pharmaceutical composition in solid form for oral administration, which contains a buffer having a pH essentially between 2 and 5.5 and which composition comprises by percentage of total weight:
- 0.8% of trimegestone,
- 3.2% of estradiol,
- 4% of HPMC,
- 1% of titanium dioxide,
- 0.15% of anhydrous disodium phosphate,
- 0.4% of citric acid monohydrate,
- 31% of maize starch,
- 0.6% of stearic acid,
- 1.2% of talc,
- 0.1% of EDTA and
- qs of lactose.
A pharmaceutical composition in solid form for oral administration, which contains a buffer having a pH essentially between 2 and 5.5 and which composition comprises by percentage of total weight:
- 0.25 mg of trimegestone,
- 2.0 mg of estradiol,
- 2.5 mg of HPMC,
- 0.6 mg of titanium dioxide,
- 0.1 mg of anhydrous disodium phosphate,
- 0.25 mg of citric acid monohydrate,
- 20 mg of maize starch,
- 38.1 mg of lactose,
- 0.4 mg of stearic acid,
- 0.8 mg of talc,
- 0.65 mg of EDTA, and qs diluent.
A pharmaceutical composition in solid form for oral administration, which contains a buffer having a pH essentially between 2 and 5.5 and which composition comprises by percentage of total weight:
- 0.5 mg of trimegestone,
- 2.0 mg of estradiol,
- 2.5 mg of HPMC,
- 0.6 mg of titanium dioxide,
- 0.1 mg of anhydrous disodium phosphate,
- 0.25 mg of citric acid monohydrate,
- 20 mg of maize starch,
- 37.85 mg of lactose,
- 0.4 mg of stearic acid,
- 0.8 mg of talc,
- 0.06mg of EDTA, and qs diluent.
Dependencies are inferred from the claim text.